Aerovate Therapeutics/AVTE

$25.24

-6.13%
-
1D1W1MYTD1YMAX

About Aerovate Therapeutics

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.

Ticker

AVTE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Benjamin Dake

Employees

51

Headquarters

Waltham, United States

AVTE Metrics

BasicAdvanced
$752.58M
Market cap
-
P/E ratio
-$2.87
EPS
-
Beta
-
Dividend rate
$752.58M
$32.42
$9.41
132.97K
7.044
-57.49%
-63.95%
-63.65%
6.851
6.876
-36.26%

What the Analysts think about AVTE

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
76.98% upside
High $65.00
Low $27.00
$25.24
Current price
$44.67
Average price target

AVTE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-20.4M
4.62%
Profit margin
0%
-

AVTE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.57%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.76
-$0.71
-$0.74
-
Expected
-$0.60
-$0.70
-$0.69
-$0.71
-$0.77
Surprise
11.67%
9.2%
2.66%
4.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Aerovate Therapeutics stock?

Aerovate Therapeutics (AVTE) has a market cap of $752.58M as of April 13, 2024.

What is the P/E ratio for Aerovate Therapeutics stock?

The price to earnings (P/E) ratio for Aerovate Therapeutics (AVTE) stock is 0 as of April 13, 2024.

Does Aerovate Therapeutics stock pay dividends?

No, Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Aerovate Therapeutics dividend payment date?

Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders.

What is the beta indicator for Aerovate Therapeutics?

Aerovate Therapeutics (AVTE) does not currently have a Beta indicator.

What is the Aerovate Therapeutics stock price target?

The target price for Aerovate Therapeutics (AVTE) stock is $44.67, which is 76.98% above the current price of $25.24. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aerovate Therapeutics stock

Buy or sell Aerovate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing